Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611216 · ClinicalTrials.gov registry record
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 164
- Enrollment target
NCT05611216 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 164 participants.
The verdict
NCT05611216 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 164 participants
- Enrollment target
Study Summary
The study was a retrospective, non-interventional patient chart review and used a panel of oncologists/hematologists from the US to collect real-world clinical outcomes of patients with CML-CP in 3L+ and those with the T315I mutation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-12-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05611216
The ClinicalTrials.gov registry entry for NCT05611216 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05611216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05611216 about?
NCT05611216 is a clinical study titled "Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation". The study was a retrospective, non-interventional patient chart review and used a panel of oncologists/hematologists from the US to collect real-world clinical outcomes of patients with CML-CP in 3L+ and those with the T315I mutation.
What is the current status of trial NCT05611216?
This trial is currently completed. The enrollment target is 164 participants. The study started on 2020-12-01. Estimated completion is 2021-12-23.
Who is sponsoring clinical trial NCT05611216?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.